Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Amortization of Deferred Charges (2020 - 2023)

Historic Amortization of Deferred Charges for Journey Medical (DERM) over the last 4 years, with Q3 2023 value amounting to $177000.0.

  • Journey Medical's Amortization of Deferred Charges fell 1194.03% to $177000.0 in Q3 2023 from the same period last year, while for Dec 2023 it was $353000.0, marking a year-over-year decrease of 5415.58%. This contributed to the annual value of $353000.0 for FY2023, which is 5415.58% down from last year.
  • Per Journey Medical's latest filing, its Amortization of Deferred Charges stood at $177000.0 for Q3 2023, which was down 1194.03% from $78000.0 recorded in Q2 2023.
  • In the past 5 years, Journey Medical's Amortization of Deferred Charges registered a high of $804000.0 during Q2 2021, and its lowest value of -$409000.0 during Q3 2021.
  • In the last 4 years, Journey Medical's Amortization of Deferred Charges had a median value of $189000.0 in 2022 and averaged $175833.3.
  • The largest annual percentage gain for Journey Medical's Amortization of Deferred Charges in the last 5 years was 14914.43% (2022), contrasted with its biggest fall of 7325.87% (2022).
  • Quarter analysis of 4 years shows Journey Medical's Amortization of Deferred Charges stood at $206000.0 in 2020, then fell by 19.9% to $165000.0 in 2021, then dropped by 8.48% to $151000.0 in 2022, then increased by 17.22% to $177000.0 in 2023.
  • Its Amortization of Deferred Charges stands at $177000.0 for Q3 2023, versus $78000.0 for Q2 2023 and $98000.0 for Q1 2023.